ArticleJCO oncology advances2026
PD-L2 Landscape and Correlation with Outcome: An Immunomic Analysis.
Article in JCO oncology advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02478931 (UCSD Profile Related Evidence Determining Individualized Cancer Therapy), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
UCSD Profile Related Evidence Determining Individualized Cancer Therapy (UCSD PREDICT)
Who cites it
2 citing papers in PubMed.
- Dendritic cell PD-L2 restrains intratumoral CD8bioRxiv : the preprint server for biology · 2026Article
- Advancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma.Current oncology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Purpose: PD-L1 and PD-L2 are inhibitory ligands that interact with PD-1 receptors, enabling immune escape. Though PD-L1 has been extensively studied, much less is known about PD-L2. PD-L2 expression could lead to incomplete blockade of the PD-1 axis by anti-PD-L1 agents and also influence activity of anti-PD-1 agents. Methods: We analyzed PD-L2 transcriptomic expression in a pan-cancer cohort (N=514; 489 patients with advanced/metastatic disease and clinical correlates available) for associations with immunomodulatory variables and outcome. Results: The most common tumors were colorectal (27% [140/514]), pancreatic (11% [55/514]), and breast cancer (9.5% [49/514]). High PD-L2 expression (≥75 Conclusions: High PD-L2 transcripts were more common in breast cancer and associated with high expression of other immune-relevant factors: PD-L1, PD-1, CD4, and TIM-3, and with TMB ≥10 mutations/megabase. High PD-L2 levels correlated with longer OS in immunotherapy-treated patients. Trial registration: NCT02478931.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.